Pulmonx is heading into ERS2026 with Zephyr Valves as interest builds in less invasive treatment options for severe COPD and emphysema. The company will present

Pulmonx is heading into ERS2026 with Zephyr Valves as interest builds in less invasive treatment options for severe COPD and emphysema. The company will present at Booth H.01 and join a lung volume reduction session focused on advanced therapies.